Boston Scientific Finds Physician Support For Wingspan Brain Stent Coverage
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific assures CMS that there is minimal risk in granting national coverage for its Wingspan brain vessel stent due to safeguards associated with the product's humanitarian device exemption
You may also be interested in...
Wingspan Coverage Policy Has Broad Implications For Humanitarian Devices
CMS' proposed coverage decision for Boston Scientific's Wingspan intracranial stent has stakeholders on edge about the precedent the agency could set in its first national decision for a humanitarian-use device
Wingspan Coverage Policy Has Broad Implications For Humanitarian Devices
CMS' proposed coverage decision for Boston Scientific's Wingspan intracranial stent has stakeholders on edge about the precedent the agency could set in its first national decision for a humanitarian-use device
Double Duty: Creating Trials To Satisfy Both FDA And CMS
Firms can do "double duty" by gathering economic data during their FDA pivotal trials to get a jump start on CMS coverage, according to Abbott Diagnostic's Barbara Calvert, director of medical products reimbursement